Columvi Granted Accelerated Approval For Selected Relapsed or Refractory Large B-cell Lymphomas

The FDA granted accelerated approval for glofitamab-gxbm (Columvi, Genentech) for the treatment of adult patients ...

JUNE 18, 2023